Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development

Pharmaceutical Research

Volumn 28, Issue 11, 2011, Pages 2669-2679

  Szeto, Hazel H ^a   Schiller, Peter W ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Ischemia reperfusion injury; Metabolic disorders; Neurodegenerative diseases; Oxidative stress; Szeto Schiller peptides

Indexed keywords

2'6' DIMETHYLTYROSYLTYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; DEXTRO ARGININE 2'6' DIMETHYLTYROSYLLYSYLPHENYLALANINAMIDE; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; OPIATE PEPTIDE; PHENYLALANYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; SMALL MOLECULE TRANSPORT AGENT; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; TYROSYLGLYCYLGLYCYLYPHENYLALANYLMETHIONINAMIDE; UNCLASSIFIED DRUG;

CARDIORENAL SYNDROME; CONSTIPATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INNER MITOCHONDRIAL MEMBRANE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; METABOLIC SYNDROME X; MITOCHONDRIAL DRUG DELIVERY SYSTEM; MITOCHONDRIAL MEMBRANE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RESPIRATION DEPRESSION; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; PROTECTIVE AGENTS;

EID: 84856228755     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0476-8     Document Type: Review

References (75)

1. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6:389-402. (Pubitemid 40577182)
2. Wanagat J, Dai DF, Rabinovitch P. Mitochondrial oxidative stress and mammalian healthspan. Mech Ageing Dev. 2010;131:527-35.
3. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med. 2010;88:993-1001.
4. Martin LJ. Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel). 2010;3:839-915.
5. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446-54.
6. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol. 2007;293: C12-21. (Pubitemid 47105003)
7. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341(Pt 2):233-49. (Pubitemid 29373645)
8. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-12. (Pubitemid 28406816)
9. Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol. 2000;40:353-88. (Pubitemid 30340687)
10. Scatena R, Martorana GE, Bottoni P, Giardina B. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life. 2004;56:477-82. (Pubitemid 39576897)
11. Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, et al. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther. 2004;311:109-14. (Pubitemid 39287789)
12. Moreno-Sanchez R, Bravo C, Vasquez C, Ayala G, Silveira LH, Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol. 1999;57:743-52. (Pubitemid 29094545)
13. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335-44. (Pubitemid 37321833)
14. Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem. 2004;279:49064-73. (Pubitemid 39625788)
15. Lesnefsky EJ, Hoppel CL. Cardiolipin as an oxidative target in cardiac mitochondria in the aged rat. Biochim Biophys Acta. 2008;1777:1020-7.
16. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging. Free Radic Biol Med. 2010;48:1286-95.
17. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006;1757:509-17.
18. Hebert SL, Lanza IR, Nair KS. Mitochondrial DNA alterations and reduced mitochondrial function in aging. Mech Ageing Dev. 2010;131:451-62.
19. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 2005;70:200-14. (Pubitemid 40512329)
20. Kono Y, Fridovich I. Superoxide radical inhibits catalase. J Biol Chem. 1982;257:5751-4.
21. Yamakura F, Taka H, Fujimura T, Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem. 1998;273:14085-9. (Pubitemid 28319114)
22. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995;11:376-81.
23. Lebovitz RM, Zhang H, Vogel H, Cartwright Jr J, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA. 1996;93:9782-7. (Pubitemid 26296686)
24. Sun J, Folk D, Bradley TJ, Tower J. Induced overexpression of mitochondrial Mn-superoxide dismutase extends the life span of adult Drosophila melanogaster. Genetics. 2002;161:661-72. (Pubitemid 34705407)
25. Jang YC, Perez VI, Song W, Lustgarten MS, Salmon AB, Mele J, et al. Overexpression of Mn superoxide dismutase does not increase life span in mice. J Gerontol A Biol Sci Med Sci. 2009;64:1114-25.
26. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005;308:1909-11. (Pubitemid 40941874)
27. Treuting PM, Linford NJ, Knoblaugh SE, Emond MJ, Morton JF, Martin GM, et al. Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci. 2008;63:813-22.
28. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, et al. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation. 2009;119:2789-97.
29. Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, Jurczak MJ, et al. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab. 2010;12:668-74.
30. Wolf N, Penn P, Pendergrass W, Van Remmen H, Bartke A, Rabinovitch P, et al. Age-related cataract progression in five mouse models for anti-oxidant protection or hormonal influence. Exp Eye Res. 2005;81:276-85. (Pubitemid 41208162)
31. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629-56.
32. Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV, et al. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (Mosc). 2008;73:1273-87.
33. Schiller PW, Nguyen TM, Berezowska I, Dupuis S, Weltrowska G, Chung NN, et al. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur J Med Chem. 2000;35:895-901.
34. Zhao GM, Wu D, Soong Y, Shimoyama M, Berezowska I, Schiller PW, et al. Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. J Pharmacol Exp Ther. 2002;302:188-96. (Pubitemid 34680437)
35. Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther. 2003;304:425-32. (Pubitemid 36008956)
36. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682-90. (Pubitemid 39318098)
37. Zhao GM, Qian X, Schiller PW, Szeto HH. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. J Pharmacol Exp Ther. 2003;307:947-54. (Pubitemid 37494211)
38. Hauser M, Donhardt AM, Barnes D, Naider F, Becker JM. Enkephalins are transported by a novel eukaryotic peptide uptake system. J Biol Chem. 2000;275:3037-41. (Pubitemid 30082997)
39. Lang VB, Langguth P, Ottiger C, Wunderli-Allenspach H, Rognan D, Rothen-Rutishauser B, et al. Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J Pharm Sci. 1997;86:846-53. (Pubitemid 27297498)
40. Tunnemann G, Ter-Avetisyan G, Martin RM, Stockl M, Herrmann A, Cardoso MC. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J Pept Sci. 2008;14:469-76. (Pubitemid 351540908)
41. Horn AS, Rodgers JR. Structural and conformational relationships between the enkephalins and the opiates. Nature. 1976;260:795-7.
42. Winterbourn CC, Parsons-Mair HN, Gebicki S, Gebicki JM, Davies MJ. Requirements for superoxide-dependent tyrosine hydroperoxide formation in peptides. Biochem J. 2004;381:241-8. (Pubitemid 38932230)
43. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol. 2005;70:1796-806. (Pubitemid 41612010)
44. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria- penetrating peptides. Chem Biol. 2008;15:375-82. (Pubitemid 351508434)
45. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal. 2008;10:601-19.
46. Whiteman M, Spencer JP, Szeto HH, Armstrong JS. Do mitochondriotropic antioxidants prevent chlorinative stressinduced mitochondrial and cellular injury? Antioxid Redox Signal. 2008;10:641-50.
47. Han Z, Varadharaj S, Giedt RJ, Zweier JL, Szeto HH, Alevriadou BR. Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells. J Pharmacol Exp Ther. 2009;329:94-101.
48. Fonck C, Baudry M. Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria. Brain Res. 2003;975:214-21. (Pubitemid 36588569)
49. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal. 2009;11:2095-104.
50. Szeto HH. Development of mitochondria-targeted aromaticcationic peptides for neurodegenerative diseases. Ann NY Acad Sci. 2008;1147:112-21.
51. Someya S, Xu J, Kondo K, Ding D, Salvi RJ, Yamasoba T, et al. Age-related hearing loss in C57BL/6J mice is mediated by Bakdependent mitochondrial apoptosis. Proc Natl Acad Sci USA. 2009;106:19432-7.
52. Li D, Lai Y, Yue Y, Rabinovitch PS, Hakim C, Duan D. Ectopic catalase expression in mitochondria by adeno-associated virus enhances exercise performance in mice. PLoS ONE. 2009;4: e6673.
53. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119:573-81.
54. Kohler JJ, Cucoranu I, Fields E, Green E, He S, Hoying A, et al. Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy. Lab Invest. 2009;89:782-90.
55. Dai DF, Chen T, Szeto H, Nieves-Cintron M, Summer V, Santana LF, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011; in press.
56. Wu D, Soong Y, Zhao GM, Szeto HH. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am J Physiol Heart Circ Physiol. 2002;283: H783-91. (Pubitemid 34790875)
57. Song W, Shin J, Lee J, Kim H, Oh D, Edelberg JM, et al. A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. Coron Artery Dis. 2005;16:407-10. (Pubitemid 41783046)
58. Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18:215-20. (Pubitemid 46608500)
59. Szeto HH, Liu S, Soong Y, Wu D, Ganger M, Darrah S, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces injury following ischemia-reperfusion injury. J Am Soc Nephrol. 2011; in press.
60. Bavinck NHP, Jimenez N, Millet BA, Szeto HH, Spector JA. SS-31: a mitochondria-specific therapy that provides significant protection against ischemia-reperfusion injury in muscle in vitro and in vivo. Washington, DC: Northeastern Society of Plastic Surgeons; 2010.
61. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62. (Pubitemid 23087289)
62. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2006;98:1141-8. (Pubitemid 44127789)
63. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis. 2010;20 Suppl 2:S609-31.
64. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med. 2008;358:1327-35. (Pubitemid 351468409)
65. Powers SK, DeCramer M, Gayan-Ramirez G, Levine S. Pressure support ventilation attenuates ventilator-induced protein modifications in the diaphragm. Crit Care. 2008;12:191.
66. Whidden MA, Smuder AJ, Wu M, Hudson MB, Nelson WB, Powers SK. Oxidative stress is required for mechanical ventilation-induced protease activation in the diaphragm. J Appl Physiol. 2010;108:1376-82.
67. Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, et al. Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness. Crit Care Med. 2011, doi:10.1097/CCM.0b013e3182190b62.
68. Powers SK, Kavazis AN, McClung JM. Oxidative stress and disuse muscle atrophy. J Appl Physiol. 2007;102:2389-97. (Pubitemid 47080773)
69. Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH, Powers SK. Mitochondrial- targeted antioxidants attenuate immobilization-induced skeletal muscle atrophy. Anaheim: Experimental Biology; 2010.
70. Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FG, Goodpaster BH, et al. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab. 2010;298:E49-58.
71. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488-96. (Pubitemid 351651106)
72. Szeto HH, Lovelace JL, Fridland G, Soong Y, Fasolo J, Wu D, et al. In vivo pharmacokinetics of selective mu-opioid peptide agonists. J Pharmacol Exp Ther. 2001;298:57-61. (Pubitemid 32574510)
73. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, et al. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res. 1997;14:152-5. (Pubitemid 27146356)
74. Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Szeto HH, et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol. 2007;18:213-22. (Pubitemid 46053434)
75. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem. 2007;282:4634-42. (Pubitemid 47100960)